Running title: New FNAIT treatment
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is defined as fetal and neonatal thrombocytopenia caused by maternal alloantibodies directed against fetal platelets due to incompatibility between fetal and maternal platelet antigens (HPAs). The majority of FNAIT cases are caused by anti-HPA-1a antibodies (1) . FNAIT is the most common cause of intracranial hemorrhage (ICH) in otherwise healthy term newborns, affecting 1:12,500 -1:25,000.The clinical outcome of FNAIT-related ICH is typically poor, and the risk of recurrence in subsequent pregnancies is high(2;3). FNAIT is also associated with increased risk of miscarriage, low birth weight, and stillbirth(1;4). husband, but miscarried five pregnancies during the 1 st trimester. We found a solution for this couple, which we believe could be a treatment option for other families in similar situation.
After obtaining approval by the Norwegian Directorate of Health, we genotyped 50 openidentity sperm donors and identified a donor with the compatible platelet antigen HPA-1bb.
Our patient conceived after in vitro fertilization using sperm from the selected donor. She had an uneventful singleton pregnancy despite high and stable maternal serum levels of anti-HPA-1a antibodies. No maternal anti-HLA class 1 antibodies were detected. A healthy newborn with normal platelet count (300 × 10 9 /L) was delivered by elective cesarean section at 38 weeks of pregnancy. The patient described has given written approval of the content.
We acknowledge the potential ethical challenges and concerns that this management option for FNAIT raise. It is important to consider if a woman has other alloantibody specificities in addition to anti-HPA-1a before undergoing this treatment, for example anti-HLA class 1
antibodies. Nonetheless, we consider use of HPA-1-matched donor sperm as a safe and possible treatment for the minority of HPA-1bb women with history of recurrent devastating FNAIT-related complications, including ICH. The alternative choice for these couples would often be to refrain from further pregnancies.
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